Results 161 to 170 of about 3,819 (202)
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis [PDF]
New England Journal of Medicine, 2017 BACKGROUND: Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran. METHODS: We performed a multicenter, prospective, open-label study to determine whether 5 g of intravenous idarucizumab would be ...
John W. Eikelboom +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Hospital Pharmacy, 2016
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Dennis J, Cada +2 more
openaire +3 more sources
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Dennis J, Cada +2 more
openaire +3 more sources
Circulation, 2015
Four non–vitamin K antagonist oral anticoagulants (NOACs), including the direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban, are currently licensed as alternatives to heparins and vitamin K antagonists for the prevention and treatment of venous thromboembolism and for the prevention of stroke in
John W. Eikelboom, Jeffrey I Weitz
exaly +3 more sources
Four non–vitamin K antagonist oral anticoagulants (NOACs), including the direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban, are currently licensed as alternatives to heparins and vitamin K antagonists for the prevention and treatment of venous thromboembolism and for the prevention of stroke in
John W. Eikelboom, Jeffrey I Weitz
exaly +3 more sources
pharma-kritik, 2017
Dieses Medikament wirkt der Antikoagulation durch den direkten Thrombinhemmer Dabigatran entgegen. Sein praktischer Nutzen ist aber bisher nicht genügend dokumentiert. Da auch sein Nebenwirkungspotential noch nicht geklärt ist, kann die Verwendung dieses sehr teuren Mittels wohl am ehesten noch im Rahmen weiterer Studien verantwortet werden.
+4 more sources
Dieses Medikament wirkt der Antikoagulation durch den direkten Thrombinhemmer Dabigatran entgegen. Sein praktischer Nutzen ist aber bisher nicht genügend dokumentiert. Da auch sein Nebenwirkungspotential noch nicht geklärt ist, kann die Verwendung dieses sehr teuren Mittels wohl am ehesten noch im Rahmen weiterer Studien verantwortet werden.
+4 more sources
Idarucizumab for Dabigatran Reversal
New England Journal of Medicine, 2015Specific reversal agents for non-vitamin K antagonist oral anticoagulants are lacking. Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.We undertook this prospective cohort study to determine the safety of 5 g of intravenous idarucizumab and its capacity to reverse the anticoagulant effects of ...
Stephan Glund +2 more
exaly +4 more sources
Dabigatran Reversal with Idarucizumab
New England Journal of Medicine, 2017 Pollack, Charles V. +2 more
exaly +7 more sources
Idarucizumab for dabigatran overdose
Clinical Toxicology, 2016An overdose of oral anticoagulants represents a challenging scenario for emergency physicians. Dabigatran, an oral direct thrombin inhibitor, is increasingly used in place of warfarin. The lack of an antidote is a concern in patients who overdose on dabigatran, even though the drug can be eliminated with hemodialysis.
Marijke Peetermans +2 more
exaly +3 more sources
Idarucizumab (Praxbind) Formulary Review
Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine, 2016Idarucizumab (Praxbind), a humanized monoclonal antibody fragment was granted accelerated approval from the Food and Drug Administration in October 2015 as the first agent to reverse the effects of a novel oral anticoagulant. The drug is indicated for dabigatran reversal in patients requiring emergency surgery/urgent procedures or with life-threatening
Jessica, Buchheit +2 more
openaire +2 more sources